Global and China Postmenopausal Vaginal Atrophy Drugs Market Insights, Forecast to 2027
Table of Contents1 Study Coverage
1.1 Postmenopausal Vaginal Atrophy Drugs Product Introduction
1.2 Market by Type
1.2.1 Global Postmenopausal Vaginal Atrophy Drugs Market Size Growth Rate by Type
1.2.2 Vaginal Gels
1.2.3 Creams
1.2.4 Tablets
1.2.5 Rings
1.2.6 Patches
1.3 Market by Application
1.3.1 Global Postmenopausal Vaginal Atrophy Drugs Market Size Growth Rate by Application
1.3.2 Offline Stores
1.3.3 Online Stores
1.4 Study Objectives
1.5 Years Considered
2 Executive Summary
2.1 Global Postmenopausal Vaginal Atrophy Drugs Market Size, Estimates and Forecasts
2.1.1 Global Postmenopausal Vaginal Atrophy Drugs Revenue 2016-2027
2.1.2 Global Postmenopausal Vaginal Atrophy Drugs Sales 2016-2027
2.2 Global Postmenopausal Vaginal Atrophy Drugs, Market Size by Region: 2016 VS 2021 VS 2027
2.3 Postmenopausal Vaginal Atrophy Drugs Historical Market Size by Region (2016-2021)
2.3.1 Global Postmenopausal Vaginal Atrophy Drugs Retrospective Market Scenario in Sales by Region: 2016-2021
2.3.2 Global Postmenopausal Vaginal Atrophy Drugs Retrospective Market Scenario in Revenue by Region: 2016-2021
2.4 Postmenopausal Vaginal Atrophy Drugs Market Estimates and Projections by Region (2022-2027)
2.4.1 Global Postmenopausal Vaginal Atrophy Drugs Sales Forecast by Region (2022-2027)
2.4.2 Global Postmenopausal Vaginal Atrophy Drugs Revenue Forecast by Region (2022-2027)
3 Global Postmenopausal Vaginal Atrophy Drugs Competitor Landscape by Players
3.1 Global Top Postmenopausal Vaginal Atrophy Drugs Manufacturers by Sales
3.1.1 Global Postmenopausal Vaginal Atrophy Drugs Sales by Manufacturer (2016-2021)
3.1.2 Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Manufacturer (2016-2021)
3.2 Global Top Postmenopausal Vaginal Atrophy Drugs Manufacturers by Revenue
3.2.1 Key Postmenopausal Vaginal Atrophy Drugs Manufacturers Covered: Ranking by Revenue
3.2.2 Global Postmenopausal Vaginal Atrophy Drugs Revenue by Manufacturers (2016-2021)
3.2.3 Global Postmenopausal Vaginal Atrophy Drugs Revenue Share by Manufacturers (2016-2021)
3.2.4 Global Postmenopausal Vaginal Atrophy Drugs Market Concentration Ratio (CR5 and HHI) (2016-2021)
3.2.5 Global Top 10 and Top 5 Companies by Postmenopausal Vaginal Atrophy Drugs Revenue in 2020
3.2.6 Global Postmenopausal Vaginal Atrophy Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Global Postmenopausal Vaginal Atrophy Drugs Price by Manufacturers
3.4 Global Postmenopausal Vaginal Atrophy Drugs Manufacturing Base Distribution, Product Types
3.4.1 Postmenopausal Vaginal Atrophy Drugs Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers Postmenopausal Vaginal Atrophy Drugs Product Type
3.4.3 Date of International Manufacturers Enter into Postmenopausal Vaginal Atrophy Drugs Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Breakdown Data by Type (2016-2027)
4.1 Global Postmenopausal Vaginal Atrophy Drugs Market Size by Type (2016-2021)
4.1.1 Global Postmenopausal Vaginal Atrophy Drugs Sales by Type (2016-2021)
4.1.2 Global Postmenopausal Vaginal Atrophy Drugs Revenue by Type (2016-2021)
4.1.3 Postmenopausal Vaginal Atrophy Drugs Average Selling Price (ASP) by Type (2016-2021)
4.2 Global Postmenopausal Vaginal Atrophy Drugs Market Size Forecast by Type (2022-2027)
4.2.1 Global Postmenopausal Vaginal Atrophy Drugs Sales Forecast by Type (2022-2027)
4.2.2 Global Postmenopausal Vaginal Atrophy Drugs Revenue Forecast by Type (2022-2027)
4.2.3 Postmenopausal Vaginal Atrophy Drugs Average Selling Price (ASP) Forecast by Type (2022-2027)
5 Breakdown Data by Application (2016-2027)
5.1 Global Postmenopausal Vaginal Atrophy Drugs Market Size by Application (2016-2021)
5.1.1 Global Postmenopausal Vaginal Atrophy Drugs Sales by Application (2016-2021)
5.1.2 Global Postmenopausal Vaginal Atrophy Drugs Revenue by Application (2016-2021)
5.1.3 Postmenopausal Vaginal Atrophy Drugs Price by Application (2016-2021)
5.2 Postmenopausal Vaginal Atrophy Drugs Market Size Forecast by Application (2022-2027)
5.2.1 Global Postmenopausal Vaginal Atrophy Drugs Sales Forecast by Application (2022-2027)
5.2.2 Global Postmenopausal Vaginal Atrophy Drugs Revenue Forecast by Application (2022-2027)
5.2.3 Global Postmenopausal Vaginal Atrophy Drugs Price Forecast by Application (2022-2027)
6 China by Players, Type and Application
6.1 China Postmenopausal Vaginal Atrophy Drugs Market Size YoY Growth 2016-2027
6.1.1 China Postmenopausal Vaginal Atrophy Drugs Sales YoY Growth 2016-2027
6.1.2 China Postmenopausal Vaginal Atrophy Drugs Revenue YoY Growth 2016-2027
6.1.3 China Postmenopausal Vaginal Atrophy Drugs Market Share in Global Market 2016-2027
6.2 China Postmenopausal Vaginal Atrophy Drugs Market Size by Players (International and Local Players)
6.2.1 China Top Postmenopausal Vaginal Atrophy Drugs Players by Sales (2016-2021)
6.2.2 China Top Postmenopausal Vaginal Atrophy Drugs Players by Revenue (2016-2021)
6.3 China Postmenopausal Vaginal Atrophy Drugs Historic Market Review by Type (2016-2021)
6.3.1 China Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Type (2016-2021)
6.3.2 China Postmenopausal Vaginal Atrophy Drugs Revenue Market Share by Type (2016-2021)
6.3.3 China Postmenopausal Vaginal Atrophy Drugs Price by Type (2016-2021)
6.4 China Postmenopausal Vaginal Atrophy Drugs Market Estimates and Forecasts by Type (2022-2027)
6.4.1 China Postmenopausal Vaginal Atrophy Drugs Sales Forecast by Type (2022-2027)
6.4.2 China Postmenopausal Vaginal Atrophy Drugs Revenue Forecast by Type (2022-2027)
6.4.3 China Postmenopausal Vaginal Atrophy Drugs Price Forecast by Type (2022-2027)
6.5 China Postmenopausal Vaginal Atrophy Drugs Historic Market Review by Application (2016-2021)
6.5.1 China Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Application (2016-2021)
6.5.2 China Postmenopausal Vaginal Atrophy Drugs Revenue Market Share by Application (2016-2021)
6.5.3 China Postmenopausal Vaginal Atrophy Drugs Price by Application (2016-2021)
6.6 China Postmenopausal Vaginal Atrophy Drugs Market Estimates and Forecasts by Application (2022-2027)
6.6.1 China Postmenopausal Vaginal Atrophy Drugs Sales Forecast by Application (2022-2027)
6.6.2 China Postmenopausal Vaginal Atrophy Drugs Revenue Forecast by Application (2022-2027)
6.6.3 China Postmenopausal Vaginal Atrophy Drugs Price Forecast by Application (2022-2027)
7 North America
7.1 North America Postmenopausal Vaginal Atrophy Drugs Market Size YoY Growth 2016-2027
7.2 North America Postmenopausal Vaginal Atrophy Drugs Market Facts & Figures by Country
7.2.1 North America Postmenopausal Vaginal Atrophy Drugs Sales by Country (2016-2021)
7.2.2 North America Postmenopausal Vaginal Atrophy Drugs Revenue by Country (2016-2021)
7.2.3 U.S.
7.2.4 Canada
8 Asia Pacific
8.1 Asia Pacific Postmenopausal Vaginal Atrophy Drugs Market Size YoY Growth 2016-2027
8.2 Asia Pacific Postmenopausal Vaginal Atrophy Drugs Market Facts & Figures by Region
8.2.1 Asia Pacific Postmenopausal Vaginal Atrophy Drugs Sales by Region (2016-2021)
8.2.2 Asia Pacific Postmenopausal Vaginal Atrophy Drugs Revenue by Region (2016-2021)
8.2.3 China
8.2.4 Japan
8.2.5 South Korea
8.2.6 India
8.2.7 Australia
8.2.8 Australia
8.2.9 Indonesia
8.2.10 Thailand
8.2.11 Malaysia
8.2.12 Philippines
8.2.13 Vietnam
9 Europe
9.1 Europe Postmenopausal Vaginal Atrophy Drugs Market Size YoY Growth 2016-2027
9.2 Europe Postmenopausal Vaginal Atrophy Drugs Market Facts & Figures by Country
9.2.1 Europe Postmenopausal Vaginal Atrophy Drugs Sales by Country (2016-2021)
9.2.2 Europe Postmenopausal Vaginal Atrophy Drugs Revenue by Country (2016-2021)
9.2.3 Germany
9.2.4 France
9.2.5 U.K.
9.2.6 Italy
10 Latin America
10.1 Latin America Postmenopausal Vaginal Atrophy Drugs Market Size YoY Growth 2016-2027
10.2 Latin America Postmenopausal Vaginal Atrophy Drugs Market Facts & Figures by Country
10.2.1 Latin America Postmenopausal Vaginal Atrophy Drugs Sales by Country (2016-2021)
10.2.2 Latin America Postmenopausal Vaginal Atrophy Drugs Revenue by Country (2016-2021)
10.2.3 Mexico
10.2.4 Brazil
10.2.5 Argentina
11 Middle East and Africa
11.1 Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Market Size YoY Growth 2016-2027
11.2 Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Market Facts & Figures by Country
11.2.1 Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Sales by Country (2016-2021)
11.2.2 Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Revenue by Country (2016-2021)
11.2.3 Turkey
11.2.4 Saudi Arabia
11.2.5 U.A.E
12 Company Profiles
12.1 Actavis plc
12.1.1 Actavis plc Corporation Information
12.1.2 Actavis plc Description and Business Overview
12.1.3 Actavis plc Postmenopausal Vaginal Atrophy Drugs Sales, Revenue and Gross Margin (2016-2021)
12.1.4 Actavis plc Postmenopausal Vaginal Atrophy Drugs Products Offered
12.1.5 Actavis plc Recent Development
12.2 Bionovo, Inc.
12.2.1 Bionovo, Inc. Corporation Information
12.2.2 Bionovo, Inc. Description and Business Overview
12.2.3 Bionovo, Inc. Postmenopausal Vaginal Atrophy Drugs Sales, Revenue and Gross Margin (2016-2021)
12.2.4 Bionovo, Inc. Postmenopausal Vaginal Atrophy Drugs Products Offered
12.2.5 Bionovo, Inc. Recent Development
12.3 Endoceutics, Inc.
12.3.1 Endoceutics, Inc. Corporation Information
12.3.2 Endoceutics, Inc. Description and Business Overview
12.3.3 Endoceutics, Inc. Postmenopausal Vaginal Atrophy Drugs Sales, Revenue and Gross Margin (2016-2021)
12.3.4 Endoceutics, Inc. Postmenopausal Vaginal Atrophy Drugs Products Offered
12.3.5 Endoceutics, Inc. Recent Development
12.4 Novo Nordisk A/S
12.4.1 Novo Nordisk A/S Corporation Information
12.4.2 Novo Nordisk A/S Description and Business Overview
12.4.3 Novo Nordisk A/S Postmenopausal Vaginal Atrophy Drugs Sales, Revenue and Gross Margin (2016-2021)
12.4.4 Novo Nordisk A/S Postmenopausal Vaginal Atrophy Drugs Products Offered
12.4.5 Novo Nordisk A/S Recent Development
12.5 Pfizer Inc.
12.5.1 Pfizer Inc. Corporation Information
12.5.2 Pfizer Inc. Description and Business Overview
12.5.3 Pfizer Inc. Postmenopausal Vaginal Atrophy Drugs Sales, Revenue and Gross Margin (2016-2021)
12.5.4 Pfizer Inc. Postmenopausal Vaginal Atrophy Drugs Products Offered
12.5.5 Pfizer Inc. Recent Development
12.6 Teva Pharmaceuticals Ltd.
12.6.1 Teva Pharmaceuticals Ltd. Corporation Information
12.6.2 Teva Pharmaceuticals Ltd. Description and Business Overview
12.6.3 Teva Pharmaceuticals Ltd. Postmenopausal Vaginal Atrophy Drugs Sales, Revenue and Gross Margin (2016-2021)
12.6.4 Teva Pharmaceuticals Ltd. Postmenopausal Vaginal Atrophy Drugs Products Offered
12.6.5 Teva Pharmaceuticals Ltd. Recent Development
12.7 Therapeutics MD, Inc.
12.7.1 Therapeutics MD, Inc. Corporation Information
12.7.2 Therapeutics MD, Inc. Description and Business Overview
12.7.3 Therapeutics MD, Inc. Postmenopausal Vaginal Atrophy Drugs Sales, Revenue and Gross Margin (2016-2021)
12.7.4 Therapeutics MD, Inc. Postmenopausal Vaginal Atrophy Drugs Products Offered
12.7.5 Therapeutics MD, Inc. Recent Development
12.8 Shionogi & Company
12.8.1 Shionogi & Company Corporation Information
12.8.2 Shionogi & Company Description and Business Overview
12.8.3 Shionogi & Company Postmenopausal Vaginal Atrophy Drugs Sales, Revenue and Gross Margin (2016-2021)
12.8.4 Shionogi & Company Postmenopausal Vaginal Atrophy Drugs Products Offered
12.8.5 Shionogi & Company Recent Development
12.9 Allergan plc
12.9.1 Allergan plc Corporation Information
12.9.2 Allergan plc Description and Business Overview
12.9.3 Allergan plc Postmenopausal Vaginal Atrophy Drugs Sales, Revenue and Gross Margin (2016-2021)
12.9.4 Allergan plc Postmenopausal Vaginal Atrophy Drugs Products Offered
12.9.5 Allergan plc Recent Development
12.10 Shionogi & Co. Ltd.
12.10.1 Shionogi & Co. Ltd. Corporation Information
12.10.2 Shionogi & Co. Ltd. Description and Business Overview
12.10.3 Shionogi & Co. Ltd. Postmenopausal Vaginal Atrophy Drugs Sales, Revenue and Gross Margin (2016-2021)
12.10.4 Shionogi & Co. Ltd. Postmenopausal Vaginal Atrophy Drugs Products Offered
12.10.5 Shionogi & Co. Ltd. Recent Development
12.11 Actavis plc
12.11.1 Actavis plc Corporation Information
12.11.2 Actavis plc Description and Business Overview
12.11.3 Actavis plc Postmenopausal Vaginal Atrophy Drugs Sales, Revenue and Gross Margin (2016-2021)
12.11.4 Actavis plc Postmenopausal Vaginal Atrophy Drugs Products Offered
12.11.5 Actavis plc Recent Development
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
13.1 Postmenopausal Vaginal Atrophy Drugs Industry Trends
13.2 Postmenopausal Vaginal Atrophy Drugs Market Drivers
13.3 Postmenopausal Vaginal Atrophy Drugs Market Challenges
13.4 Postmenopausal Vaginal Atrophy Drugs Market Restraints
14 Value Chain and Sales Channels Analysis
14.1 Value Chain Analysis
14.2 Postmenopausal Vaginal Atrophy Drugs Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
16.3 Disclaimer
List of TablesTable 1. Global Postmenopausal Vaginal Atrophy Drugs Market Size Growth Rate by Type, 2016 VS 2021 VS 2027 (US$ Million)
Table 2. Major Manufacturers of Vaginal Gels
Table 3. Major Manufacturers of Creams
Table 4. Major Manufacturers of Tablets
Table 5. Major Manufacturers of Rings
Table 6. Major Manufacturers of Patches
Table 7. Global Postmenopausal Vaginal Atrophy Drugs Market Size Growth Rate by Application (2021-2027) & (K Units)
Table 8. Global Postmenopausal Vaginal Atrophy Drugs Market Size by Region (K Units) & (US$ Million), 2016 VS 2021 VS 2027
Table 9. Global Postmenopausal Vaginal Atrophy Drugs Sales by Regions (2016-2021) & (K Units)
Table 10. Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Regions (2016-2021)
Table 11. Global Postmenopausal Vaginal Atrophy Drugs Revenue by Regions (2016-2021) & (US$ Million)
Table 12. Global Postmenopausal Vaginal Atrophy Drugs Sales Forecast by Region (2022-2027) & (K Units)
Table 13. Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share Forecast by Region (2022-2027)
Table 14. Global Postmenopausal Vaginal Atrophy Drugs Revenue Forecast by Region (2022-2027) & (US$ Million)
Table 15. Global Postmenopausal Vaginal Atrophy Drugs Revenue Market Share Forecast by Region (2022-2027)
Table 16. Global Postmenopausal Vaginal Atrophy Drugs Sales by Manufacturers (2016-2021) (K Units)
Table 17. Global Postmenopausal Vaginal Atrophy Drugs Sales Share by Manufacturers (2016-2021)
Table 18. Ranking of Global Top Postmenopausal Vaginal Atrophy Drugs Manufacturers by Revenue (US$ Million) in 2020
Table 19. Postmenopausal Vaginal Atrophy Drugs Revenue by Manufacturers (2016-2021) (US$ Million)
Table 20. Postmenopausal Vaginal Atrophy Drugs Revenue Share by Manufacturers (2016-2021)
Table 21. Global Postmenopausal Vaginal Atrophy Drugs Manufacturers Market Concentration Ratio (CR5 and HHI) & (2016-2021)
Table 22. Global Postmenopausal Vaginal Atrophy Drugs by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Postmenopausal Vaginal Atrophy Drugs as of 2020)
Table 23. Key Manufacturers Postmenopausal Vaginal Atrophy Drugs Price (2016-2021) (USD/Unit)
Table 24. Postmenopausal Vaginal Atrophy Drugs Manufacturers Manufacturing Base Distribution and Headquarters
Table 25. Manufacturers Postmenopausal Vaginal Atrophy Drugs Product Type
Table 26. Date of International Manufacturers Enter into Postmenopausal Vaginal Atrophy Drugs Market
Table 27. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 28. Global Postmenopausal Vaginal Atrophy Drugs Sales by Type (2016-2021) (K Units)
Table 29. Global Postmenopausal Vaginal Atrophy Drugs Sales Share by Type (2016-2021)
Table 30. Global Postmenopausal Vaginal Atrophy Drugs Revenue by Type (2016-2021) (US$ Million)
Table 31. Global Postmenopausal Vaginal Atrophy Drugs Revenue Share by Type (2016-2021)
Table 32. Postmenopausal Vaginal Atrophy Drugs Average Selling Price (ASP) by Type (2016-2021) & (USD/Unit)
Table 33. Global Postmenopausal Vaginal Atrophy Drugs Sales Forecast by Type (2022-2027) & (K Units)
Table 34. Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share Forecast by Type (2022-2027)
Table 35. Global Postmenopausal Vaginal Atrophy Drugs Revenue Forecast V (2022-2027) & (US$ Million)
Table 36. Global Postmenopausal Vaginal Atrophy Drugs Revenue Market Share Forecast by Type (2022-2027)
Table 37. Global Postmenopausal Vaginal Atrophy Drugs Average Selling Price (ASP) Forecast by Type (2022-2027) & (USD/Unit)
Table 38. Global Postmenopausal Vaginal Atrophy Drugs Sales by Application (2016-2021) (K Units)
Table 39. Global Postmenopausal Vaginal Atrophy Drugs Sales Share by Application (2016-2021)
Table 40. Global Postmenopausal Vaginal Atrophy Drugs Revenue by Application (2016-2021) (US$ Million)
Table 41. Global Postmenopausal Vaginal Atrophy Drugs Revenue Share by Application (2016-2021)
Table 42. Postmenopausal Vaginal Atrophy Drugs Average Selling Price (ASP) by Application (2016-2021) & (USD/Unit)
Table 43. Global Postmenopausal Vaginal Atrophy Drugs Sales Forecast by Application (2022-2027) & (K Units)
Table 44. Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share Forecast by Application (2022-2027)
Table 45. Global Postmenopausal Vaginal Atrophy Drugs Revenue Forecast by Application (2022-2027) & (US$ Million)
Table 46. Global Postmenopausal Vaginal Atrophy Drugs Revenue Market Share Forecast by Application (2022-2027)
Table 47. Global Postmenopausal Vaginal Atrophy Drugs Average Selling Price (ASP) Forecast by Application (2022-2027) & (USD/Unit)
Table 48. China Postmenopausal Vaginal Atrophy Drugs Sales (K Units) of Key Companies (2016-2021)
Table 49. China Postmenopausal Vaginal Atrophy Drugs Sales Share by Company (2016-2021)
Table 50. China Postmenopausal Vaginal Atrophy Drugs Revenue (US$ Million) by Company (2016-2021)
Table 51. China Postmenopausal Vaginal Atrophy Drugs Revenue Share by Company (2016-2021)
Table 52. China Postmenopausal Vaginal Atrophy Drugs Sales (K Units) by Type (2016-2021)
Table 53. China Postmenopausal Vaginal Atrophy Drugs Sales Share by Type (2016-2021)
Table 54. China Postmenopausal Vaginal Atrophy Drugs Revenue (US$ Million) Market Share by Type (2016-2021)
Table 55. China Postmenopausal Vaginal Atrophy Drugs Price (USD/Unit) by Type (2016-2021)
Table 56. China Postmenopausal Vaginal Atrophy Drugs Sales (K Units) by Type (2022-2027)
Table 57. China Postmenopausal Vaginal Atrophy Drugs Sales Share by Type (2022-2027)
Table 58. China Postmenopausal Vaginal Atrophy Drugs Revenue (US$ Million) Market Share by Type (2022-2027)
Table 59. China Postmenopausal Vaginal Atrophy Drugs Revenue Share by Type (2022-2027)
Table 60. China Postmenopausal Vaginal Atrophy Drugs Price (USD/Unit) by Type (2022-2027)
Table 61. China Postmenopausal Vaginal Atrophy Drugs Sales (K Units) by Application (2016-2021)
Table 62. China Postmenopausal Vaginal Atrophy Drugs Sales Share by Application (2016-2021)
Table 63. China Postmenopausal Vaginal Atrophy Drugs Revenue (US$ Million) Market Share by Application (2016-2021)
Table 64. China Postmenopausal Vaginal Atrophy Drugs Price (USD/Unit) by Application (2016-2021)
Table 65. China Postmenopausal Vaginal Atrophy Drugs Sales (K Units) by Application (2022-2027)
Table 66. China Postmenopausal Vaginal Atrophy Drugs Sales Share by Application (2022-2027)
Table 67. China Postmenopausal Vaginal Atrophy Drugs Revenue (US$ Million) Market Share by Application (2022-2027)
Table 68. China Postmenopausal Vaginal Atrophy Drugs Revenue Share by Application (2022-2027)
Table 69. China Postmenopausal Vaginal Atrophy Drugs Price (USD/Unit) by Application (2022-2027)
Table 70. North America Postmenopausal Vaginal Atrophy Drugs Sales by Country (2016-2021) & (K Units)
Table 71. North America Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Country (2016-2021)
Table 72. North America Postmenopausal Vaginal Atrophy Drugs Revenue by Country (2016-2021) & (US$ Million)
Table 73. North America Postmenopausal Vaginal Atrophy Drugs Revenue Market Share by Country (2016-2021)
Table 74. Asia Pacific Postmenopausal Vaginal Atrophy Drugs Sales by Region (2016-2021) & (K Units)
Table 75. Asia Pacific Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Region (2016-2021)
Table 76. Asia Pacific Postmenopausal Vaginal Atrophy Drugs Revenue by Region (2016-2021) & (US$ Million)
Table 77. Asia Pacific Postmenopausal Vaginal Atrophy Drugs Revenue Market Share by Region (2016-2021)
Table 78. Europe Postmenopausal Vaginal Atrophy Drugs Sales by Country (2016-2021) & (K Units)
Table 79. Europe Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Country (2016-2021)
Table 80. Europe Postmenopausal Vaginal Atrophy Drugs Revenue by Country (2016-2021) & (US$ Million)
Table 81. Europe Postmenopausal Vaginal Atrophy Drugs Revenue Market Share by Country (2016-2021)
Table 82. Latin America Postmenopausal Vaginal Atrophy Drugs Sales by Country (2016-2021) & (K Units)
Table 83. Latin America Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Country (2016-2021)
Table 84. Latin Americaa Postmenopausal Vaginal Atrophy Drugs Revenue by Country (2016-2021) & (US$ Million)
Table 85. Latin America Postmenopausal Vaginal Atrophy Drugs Revenue Market Share by Country (2016-2021)
Table 86. Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Sales by Country (2016-2021) & (K Units)
Table 87. Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Country (2016-2021)
Table 88. Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Revenue by Country (2016-2021) & (US$ Million)
Table 89. Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Revenue Market Share by Country (2016-2021)
Table 90. Actavis plc Corporation Information
Table 91. Actavis plc Description and Business Overview
Table 92. Actavis plc Postmenopausal Vaginal Atrophy Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2016-2021)
Table 93. Actavis plc Postmenopausal Vaginal Atrophy Drugs Product
Table 94. Actavis plc Recent Development
Table 95. Bionovo, Inc. Corporation Information
Table 96. Bionovo, Inc. Description and Business Overview
Table 97. Bionovo, Inc. Postmenopausal Vaginal Atrophy Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2016-2021)
Table 98. Bionovo, Inc. Product
Table 99. Bionovo, Inc. Recent Development
Table 100. Endoceutics, Inc. Corporation Information
Table 101. Endoceutics, Inc. Description and Business Overview
Table 102. Endoceutics, Inc. Postmenopausal Vaginal Atrophy Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2016-2021)
Table 103. Endoceutics, Inc. Product
Table 104. Endoceutics, Inc. Recent Development
Table 105. Novo Nordisk A/S Corporation Information
Table 106. Novo Nordisk A/S Description and Business Overview
Table 107. Novo Nordisk A/S Postmenopausal Vaginal Atrophy Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2016-2021)
Table 108. Novo Nordisk A/S Product
Table 109. Novo Nordisk A/S Recent Development
Table 110. Pfizer Inc. Corporation Information
Table 111. Pfizer Inc. Description and Business Overview
Table 112. Pfizer Inc. Postmenopausal Vaginal Atrophy Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2016-2021)
Table 113. Pfizer Inc. Product
Table 114. Pfizer Inc. Recent Development
Table 115. Teva Pharmaceuticals Ltd. Corporation Information
Table 116. Teva Pharmaceuticals Ltd. Description and Business Overview
Table 117. Teva Pharmaceuticals Ltd. Postmenopausal Vaginal Atrophy Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2016-2021)
Table 118. Teva Pharmaceuticals Ltd. Product
Table 119. Teva Pharmaceuticals Ltd. Recent Development
Table 120. Therapeutics MD, Inc. Corporation Information
Table 121. Therapeutics MD, Inc. Description and Business Overview
Table 122. Therapeutics MD, Inc. Postmenopausal Vaginal Atrophy Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2016-2021)
Table 123. Therapeutics MD, Inc. Product
Table 124. Therapeutics MD, Inc. Recent Development
Table 125. Shionogi & Company Corporation Information
Table 126. Shionogi & Company Description and Business Overview
Table 127. Shionogi & Company Postmenopausal Vaginal Atrophy Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2016-2021)
Table 128. Shionogi & Company Product
Table 129. Shionogi & Company Recent Development
Table 130. Allergan plc Corporation Information
Table 131. Allergan plc Description and Business Overview
Table 132. Allergan plc Postmenopausal Vaginal Atrophy Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2016-2021)
Table 133. Allergan plc Product
Table 134. Allergan plc Recent Development
Table 135. Shionogi & Co. Ltd. Corporation Information
Table 136. Shionogi & Co. Ltd. Description and Business Overview
Table 137. Shionogi & Co. Ltd. Postmenopausal Vaginal Atrophy Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2016-2021)
Table 138. Shionogi & Co. Ltd. Product
Table 139. Shionogi & Co. Ltd. Recent Development
Table 140. Postmenopausal Vaginal Atrophy Drugs Market Trends
Table 141. Postmenopausal Vaginal Atrophy Drugs Market Drivers
Table 142. Postmenopausal Vaginal Atrophy Drugs Market Challenges
Table 143. Postmenopausal Vaginal Atrophy Drugs Market Restraints
Table 144. Postmenopausal Vaginal Atrophy Drugs Customers List
Table 145. Postmenopausal Vaginal Atrophy Drugs Distributors List
Table 146. Research Programs/Design for This Report
Table 147. Key Data Information from Secondary Sources
Table 148. Key Data Information from Primary Sources
List of FiguresFigure 1. Postmenopausal Vaginal Atrophy Drugs Product Picture
Figure 2. Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Type in 2020 & 2027
Figure 3. Vaginal Gels Product Picture
Figure 4. Creams Product Picture
Figure 5. Tablets Product Picture
Figure 6. Rings Product Picture
Figure 7. Patches Product Picture
Figure 8. Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Application in 2020 & 2027
Figure 9. Offline Stores
Figure 10. Online Stores
Figure 11. Postmenopausal Vaginal Atrophy Drugs Report Years Considered
Figure 12. Global Postmenopausal Vaginal Atrophy Drugs Market Size, (US$ Million), 2016 VS 2021 VS 2027
Figure 13. Global Postmenopausal Vaginal Atrophy Drugs Market Size 2016-2027 (US$ Million)
Figure 14. Global Postmenopausal Vaginal Atrophy Drugs Sales 2016-2027 (K Units)
Figure 15. Global Postmenopausal Vaginal Atrophy Drugs Market Size Market Share by Region: 2021 Versus 2027
Figure 16. Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Region (2016-2021)
Figure 17. Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Region in 2020
Figure 18. Global Postmenopausal Vaginal Atrophy Drugs Revenue Market Share by Region (2016-2021)
Figure 19. Global Postmenopausal Vaginal Atrophy Drugs Revenue Market Share by Region in 2020
Figure 20. Global Postmenopausal Vaginal Atrophy Drugs Sales Share by Manufacturer in 2020
Figure 21. The Top 10 and 5 Players Market Share by Postmenopausal Vaginal Atrophy Drugs Revenue in 2020
Figure 22. Postmenopausal Vaginal Atrophy Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2016 VS 2020
Figure 23. Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Type (2016-2021)
Figure 24. Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Type in 2020
Figure 25. Global Postmenopausal Vaginal Atrophy Drugs Revenue Market Share by Type (2016-2021)
Figure 26. Global Postmenopausal Vaginal Atrophy Drugs Revenue Market Share by Type in 2020
Figure 27. Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Application (2016-2021)
Figure 28. Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Application in 2020
Figure 29. Global Postmenopausal Vaginal Atrophy Drugs Revenue Market Share by Application (2016-2021)
Figure 30. Global Postmenopausal Vaginal Atrophy Drugs Revenue Market Share by Application in 2020
Figure 31. China Postmenopausal Vaginal Atrophy Drugs Sales Growth Rate 2016-2027 (K Units)
Figure 32. China Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate 2016-2027 (US$ Million)
Figure 33. China Postmenopausal Vaginal Atrophy Drugs Market Share in Global Market 2016-2027
Figure 34. China 5 and 10 Largest Postmenopausal Vaginal Atrophy Drugs Players Market Share by Revenue in Postmenopausal Vaginal Atrophy Drugs in 2020
Figure 35. China Postmenopausal Vaginal Atrophy Drugs Revenue Share by Type (2016-2021)
Figure 36. China Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate by Type in 2016 & 2020
Figure 37. China Postmenopausal Vaginal Atrophy Drugs Revenue Share by Application (2016-2021)
Figure 38. China Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate by Application in 2016 & 2020
Figure 39. North America Postmenopausal Vaginal Atrophy Drugs Sales Growth Rate 2016-2021 (K Units)
Figure 40. North America Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate 2016-2021 (US$ Million)
Figure 41. North America Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Country in 2020
Figure 42. North America Postmenopausal Vaginal Atrophy Drugs Revenue Market Share by Country in 2020
Figure 43. U.S. Postmenopausal Vaginal Atrophy Drugs Sales Growth Rate (2016-2021) (K Units)
Figure 44. U.S. Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 45. Canada Postmenopausal Vaginal Atrophy Drugs Sales Growth Rate (2016-2021) (K Units)
Figure 46. Canada Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 47. Europe Postmenopausal Vaginal Atrophy Drugs Sales Growth Rate 2016-2